ISP (N = 32) | CSP (N = 32) | p | |
---|---|---|---|
Age (y.o) | 40.9 ± 12.7 | 45.7 ± 15.7 | 0.22 |
Male gender (n [%]) | 15 (46.9) | 16 (50.0) | 0.80 |
BMI (kg/m2) | 22.3 ± 3.9 | 22.6 ± 3.1 | 0.85 |
HT (n [%]) | 18 (56.3) | 20 (63.0) | 0.88 |
DM (n [%]) | 1 (3.1) | 3 (1.9) | 0.61 |
SBP (mmHg) | 116.6 ± 14.8 | 121.5 ± 13.9 | 0.18 |
DBP (mmHg) | 71.5 ± 11.6 | 71.8 ± 8.1 | 0.77 |
RAS inhibitor use (n [%]) | 13 (40.6) | 19 (59.0) | 0.13 |
Proteinuria (g/gCr) | 0.93 (0.61–1.37) | 0.91 (0.35–1.52) | 0.67 |
Categories for proteinuria (g/gCr) | 0.17 | ||
≧1.0 (n [%]) | 14 (43.8) | 15 (46.9) | |
0.5–0.9 (n [%]) | 11 (34.4) | 5 (15.6) | |
< 0.5 (n [%]) | 7 (21.9) | 12 (37.5) | |
Hematuria (n [%]) | 29 (90.6) | 30 (93.8) | 0.64 |
eGFR (mL/min/1.73 m2) | 62.5 (33.9–80.7) | 58.4 (39.2–76.6) | 0.93 |
CKD stage | 0.22 | ||
1–2 (n [%]) | 18 (56.3) | 15 (46.9) | |
3 (n [%]) | 9 (28.1) | 15 (46.9) | |
4 (n [%]) | 5 (15.6) | 2 (6.2) | |
5 (n [%]) | 0 (0) | 0 (0) | |
IgA (mg/dL) | 346.6 ± 147.9 | 363.6 ± 119.1 | 0.36 |
C3 (mg/dL) | 97.4 ± 19.8 | 104.1 ± 15.5 | 0.17 |
IgA/C3 | 3.7 ± 1.9 | 3.6 ± 1.2 | 0.73 |
Tonsillectomy (n [%]) | 4 (12.5) | 5 (15.6) | 0.72 |